<Table> <Tr> <Td> </Td> <Td> This article includes a list of references, but its sources remain unclear because it has insufficient inline citations . Please help to improve this article by introducing more precise citations . (January 2014) (Learn how and when to remove this template message) </Td> </Tr> </Table> <Tr> <Td> </Td> <Td> This article includes a list of references, but its sources remain unclear because it has insufficient inline citations . Please help to improve this article by introducing more precise citations . (January 2014) (Learn how and when to remove this template message) </Td> </Tr> <P> A serotonin--norepinephrine--dopamine reuptake inhibitor (SNDRI), also known as a triple reuptake inhibitor (TRI), is a type of drug that acts as a combined reuptake inhibitor of the monoamine neurotransmitters serotonin, norepinephrine, and dopamine . It does this by concomitantly inhibiting the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT), respectively . Inhibition of the reuptake of these neurotransmitters increases their extracellular concentrations and, therefore, results in an increase in serotonergic, adrenergic, and dopaminergic neurotransmission . </P> <P> SNDRIs were developed as potential antidepressants and treatments for other disorders, such as obesity, cocaine addiction, attention - deficit hyperactivity disorder (ADHD), and chronic pain . They are an extension of selective serotonin reuptake inhibitors (SSRIs) and serotonin - norepinephrine reuptake inhibitors (SNRIs) whereby the addition of dopaminergic action is thought to have the possibility of heightening therapeutic benefit . However, increased side effects and abuse potential are potential concerns of these agents relative to their SSRI and SNRI counterparts . </P>

What drug prolongs the effects of dopamine norepinephrine and serotonin